Show You Know: Cardiovascular Risk Reduction and PCSK9 Inhibitors

Cardiovascular Risk Reduction and PCSK9 Inhibitors

This resource is designed for pharmacists to assess their knowledge regarding PCSK9 inhibitors' role in therapy and recent measures to improve access and affordability of PCSK9 inhibitors (new NDCs).

Take this quiz to learn more about using PCSK9 inhibitors in therapy with patients with atherosclerotic cardiovascular disease (ASCVD).

Q1: Which one of the following individuals is considered a very high-risk patient with clinical ASCVD according to the 2018 AHA–ACC-Multisociety cholesterol guideline for the purpose of implementing maximal LDL-C lowering pharmacotherapy?*

a. A 75-year-old woman with diabetes, hypertension, and hypercholesterolemia.

b. A 65-year-old man with a history of myocardial infarction and type 2 diabetes.

c. A 50-year-old woman with heart failure with reduced ejection fraction.

d. A 30-year-old man with heterozygous familial hypercholesterolemia.

1
Q1
2
Q2
3
Q3
4
Q4
5
Q5
6
Final Results

Share

Cardiovascular Risk Reduction and PCSK9 Inhibitors

Q1: Which one of the following individuals is considered a very high-risk patient with clinical ASCVD according to the 2018 AHA–ACC-Multisociety cholesterol guideline for the purpose of implementing maximal LDL-C lowering pharmacotherapy?*